Immunologic attributes of cytokine mobilized peripheral blood stem cells and recovery following transplantation

Bone Marrow Transplantation

Volumn 17, Issue 1, 1996, Pages 101-109

  Talmadge, J E ^a   Reed, E C ^a   Kessinger, A ^a   Kuszynski, C A ^a   Perry, G A ^b   Gordy, C L ^a   Mills, K C ^a   Thomas, M L ^a   Pirruccello, S J ^a   Letheby, B A ^a   Arneson, M A ^a   Jackson, J D ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

CD34; FACS; Immune function; Natural suppressor cells; Peripheral blood stem cell transplantation

Indexed keywords

CD34 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PHYTOHEMAGGLUTININ;

APHERESIS; ARTICLE; AUTOTRANSPLANTATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEMATOPOIETIC SYSTEM; HUMAN; IMMUNE SYSTEM; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE; MAJOR CLINICAL STUDY; MITOGENESIS; MONOCYTE; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; PHENOTYPE; PRIORITY JOURNAL; SOLID TUMOR; STEM CELL TRANSPLANTATION; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE ACTIVATION;

ANTIGENS, CD34; ANTIGENS, CD4; ANTIGENS, CD8; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOPHENOTYPING; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES, REGULATORY;

EID: 13344269682     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Kessinger A. Armitage J, Smith D et al. High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma. Blood 1989; 74: 1260-1265.
2. Sharp J, Crouse D. Marrow contamination: detection and significance. In: Armitage J, Antman K (eds). High-Dose Cancer Therapy: Pharmacology, Hematopoietins, Stem Cells. Williams & Wilkins: Baltimore, 1992, p 226-248.
3. Sharp J, Joshi S, Armitage J et al. Significance of detection of occult non-Hodgkin's lymphoma in histologically uninvolved bone marrow by a culture technique. Blood 1992; 79: 1074-1080.
4. To L, Roberts M, Haylock D et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 1992; 9: 277-284.
5. Henon PR, Liang H, Beck-Wirth G et al. Comparison of hematopoietic and immune recovery after autologous bone marrow or blood stem cell transplants. Bone Marrow Transplant 1992; 9: 285-291.
6. Juttner C, To LB, Ho J et al. Early lympho-hemopoietic recovery after autografting using peripheral blood stem cells in acute non-lymphoblastic leukemia. Transplant Proc 1988; 20: 40-42.
7. Fermand JP, Levy Y, Gerota J et al. Treatment of aggressive multiple myeloma by high-dose chemotherapy and total body irradiation followed by blood stem cells autologous graft. Blood 1989; 73: 20-23.
8. Korbling M, Holle R, Haas R et al. Autologous blood stemcell transplantation in patients with advanced Hodgkin's disease and prior radiation to the pelvic site. J Clin Oncol 1990; 8: 978-985.
9. Huan SD, Hester J, Spitzer G et al. Influence of mobilized peripheral blood cells on the hematopoietic recovery by autologous marrow and recombinant human granulocyte-macrophage colony-stimulating factor after high-dose cyclophosphamide, etoposide, and cisplatin. Blood 1992; 79: 3388-3393.
10. Pierelli L, Iacone A, Quaglietta AM et al. Haemopoietic reconstitution after autologous blood stem cell transplantation in patients with malignancies: a multicenter retrospective study. Br J Haematol 1994; 86: 70-75.
11. Vose J, Anderson J, Kessinger A et al. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 1846-1851.
12. Freedman AS, Nedler LM. Which patients with relapsed non-Hodgkin's lymphoma benefit from high-dose therapy and hematopoietic stem-cell transplantation? J Clin Oncol 1993; 11: 1841-1843 (editorial).
13. To L, Juttner C, Stomski F et al. Immune reconstitution following peripheral blood stem cell autografting. Bone Marrow Transplant 1987; 2: 111-112.
14. Kiesel S, Pezzutto A, Korbling M et al. Autologous peripheral blood stem cell transplantation: analysis of autografted cells and lymphocyte recovery. Transplant Proc 1989; 21: 3084-3088.
15. Scambia G, Panici PB, Pierelli L et al. Immunological reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation for advanced ovarian cancer. Eur J Cancer 1993; 29A: 1518-1522.
16. Roberts MM, To LB, Gillis D et al. Immune reconstitution following peripheral blood stem cell transplantation, autologous bone marrow transplantation and allogeneic bone marrow transplantation. Bone Marrow Transplant 1993; 12: 469-475.
17. Ashihara E, Shimazaki C, Yamagata N et al. Reconstitution of lymphocyte subsets after peripheral blood stem cell transplantation: two color cytometric analysis. Bone Marrow Transplant 1994; 13: 377-381.
18. Gordy C, Thomas M. Reed E et al. Immune function and phenotype of peripheral blood and bone marrow stem cell products and peripheral blood reconstitution. Blood 1993; 82: 648a.
19. Weaver CH, Longin K, Buckner CD, Bensinger W. Lymphocyte content in peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant 1994; 13: 411-415.
20. Ho AD, Maruyama M, Maghazachi A et al. Soluble CD4, soluble CD25, lymphopoietic recovery, and endogenous cytokines after high-dose chemotherapy and blood stem cell transplantation. Blood 1994; 84: 3550-3557.
21. Bishop MR, Anderson JR, Jackson JD et al. High-dose therapy and peripheral blood progenitor cell transplantation: effects of recombinant human granulocyte-macrophage colony-stimulating factor on the autograft. Blood 1994; 83: 610-616.
22. Badger AM, King AG, Talmadge JE et al. Induction of nonspecific suppressor cells by a novel azaspirane, SK&F 105685, an immunomodulatory compound with therapeutic activity in animal models of autoimmune disease. J Autoimmunity 1990; 3: 485-500.
23. Neubauer MA, Benyunes MC, Thomson JA et al. Lymphokine-activated killer (LAK) precursor cell activity is present in infused peripheral blood stem cells and in the blood after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1994; 13: 311-316.
24. Schmitz-Wolf IG, Dejbakhsh-Jones S, Ginzton N et al. T cell subsets and suppressor cells in human bone marrow. Blood 1992; 80: 3242-3250.
25. - αβ bone marrow T cells with suppressor activity. J Immunol 1992; 148; 373-380.
26. 1. J Immunol 1989; 143: 491-498.
27. Holda JH, Maier T, Claman HN. Natural suppressor activity in graft versus-host spleen and normal bone marrow is augmented by IL-2 and interferon-γ. J Immunol 1986; 137: 3538-3543.
28. Dorshkind K, Rosse C, Physical, biological, and phenotypic properties of natural regulatory cells in murine bone marrow. Am J Anat 1982; 164: 1-17.
29. Maier T, Holda JH, Claman HN. Natural suppressor (NS) cells, members of the LGL regulatory family, Immunol Today 1986; 7: 312-318.
30. Slavin S, Strober S. Induction of allograft tolerance after total lymphoid irradiation (TLI): development of suppressor cells of the mixed leukocyte reaction (MLR). J Immunol 1979; 123: 942-946.
31. Holda JH, Maier T, Claman HN. Graft-versus-host reactions (GVHR) across minor murine histocompatibility barriers. I. Impairment of mitogen responses and suppressor cell activity. J Immunol 1985; 134: 1397-1402.
32. King DP, Strober S, Kaplan HS. Suppression of the mixed leukocyte response and graft-versus-host disease by spleen cells following total lymphoid irradiation (TLI). J Immunol 1981; 126: 1140-1145.
33. Weigensberg M, Morecki S, Weiss L et al. Suppression of cell-mediated responses after total lymphoid irradiation (TLI). I. Characterization of suppressor cells of the mixed lymphocyte reaction. J Immunol 1984; 132: 971-978.
34. McIntosh KR, Segre M, Segre D. Characterization of cycaophosphamide-induced suppressor cells. Immunopharmacology 1982; 4: 279-289.
35. Nikcevich DA, Duffie GP. Young MR et al. Stimulation of suppressor cells in the bone marrow and spleens of high-dose cyclophosphamide-treated C57BL/6 mice. Cell Immunol 1987; 109: 349-359.
36. Linch DC, Knott LJ, Thomas RM et al. T cell regeneration after allogeneic and autologous bone marrow transplantation. Br J Haematol 1983; 53: 451-458.
37. Ueda M, Harada M, Shiobara S et al. T lymphocyte reconstitution in long-term survivors after allogeneic and autologous marrow transplantation. Transplantation 1984; 37: 552-556.
38. Armitage RJ, Goldstone AH, Richards JD, Cawley JC. Lymphocyte function after autologous bone marrow transplantation (BMT): a comparison with patients treated with allogeneic BMT and with chemotherapy. Br J Haematol 1986; 63: 637-647.
39. Olsen GA, Gockerman JP, Bast RC jr et al. Altered immunologic reconstitution after standard-dose chemotherapy or highdose chemotherapy with autologous bone marrow support. Transplantation 1988; 46: 57-60.
40. Bender JG, To LB, Williams S, Schwartzberg LS. Defining a therapeutic dose of peripheral blood stem cells. J Hematother 1992; 1: 329-341.